WST
Premium GrowerAI neutralWest Pharmaceutical Services, Inc. · Healthcare · United States · $27.6B cap · $278.6M/day traded
$412.86 +0.1% · close 11 Nov · scored 12 Nov
Premium Grower: Strong business with the market behind it, priced at a premium.
Around its 29 Oct results, analysts left next year's EPS estimate little changed.
As of 12 Nov 2026, the MoatMap Score for West Pharmaceutical Services, Inc. (WST) is 81/100, ranked against 25,000+ stocks in 38 markets (Quality 80, Value 20, Momentum 79, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
West Pharmaceutical makes the rubber stoppers, seals and delivery components used in injectable drugs, a niche where regulatory qualification makes switching suppliers slow and costly. Demand from GLP-1 weight-loss drugs and biologics supports its high-value products, and the company has been buying back shares. It is a genuine quality business, but the shares trade on a rich valuation after a strong run, insiders have been modest net sellers, and there is no clear reason the market is underpricing its growth.
ABOUT WEST PHARMACEUTICAL SERVICES, INC.
Read
West Pharmaceutical Services is a global leader in designing and manufacturing high-quality containment and delivery systems for injectable drugs and other healthcare products, including stoppers, seals, and syringe components. The company's competitive moat is built upon its critical position as a trusted partner to pharmaceutical companies, extensive regulatory expertise, and proprietary technologies, which create high switching costs for drug packaging. West is a niche market leader, integral to the biopharmaceutical supply chain.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9B | 2.9B | 2.9B | 3.1B | 2.1% | 3.4B | 3.4B | 3.6B | 8.6% |
| EPS | 7.87 | 7.98 | 6.75 | 6.83 | -4.6% | 8.91 | 8.86 | 9.74 | 19.4% |
| Shares | 74.1M | 73.5M | 72.3M | 72.0M | -2.8% | 69.7M | — | — | — |
| Debt | 317.9M | 309.0M | 302.3M | 321.1M | 0.3% | 313.9M | — | — | — |
| Equity | 2.7B | 2.9B | 2.7B | 3.2B | 5.8% | — | — | — | — |
| Op CF | 724.0M | 776.5M | 653.4M | 754.8M | 1.4% | 654.5M | — | — | — |
| Inv CF | -288.2M | -368.7M | -378.7M | -285.9M | — | — | — | — | — |
| Fin CF | -293.6M | -459.6M | -622.6M | -185.1M | — | — | — | — | — |
Above its 200-day average and 6% below its 52-week high.
Calmer than 70% of stocks we rank over the past year (volatility 31% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WST are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| WST | West Pharmaceutical Services, Inc.(you) | $27.6B | 81 |
| RMD | ResMed Inc. | $35.6B | 88 |
| BDX | Becton, Dickinson and Company | $54.2B | 87 |
| BAX | Baxter International Inc. | $13.1B | 74 |
| AVTR | Avantor, Inc. | $11.7B | 74 |
| ALGN | Align Technology, Inc. | $11.0B | 88 |
| SOLV | Solventum Corporation | $14.5B | 66 |
| COO | The Cooper Companies, Inc. | $11.6B | 68 |
| MMSI | Merit Medical Systems, Inc. | $5.6B | 88 |
| ATR | AptarGroup, Inc. | $8.0B | 65 |
Peer medians: ROE -31.0% · P/E 25.7x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.